Download Report Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024

“Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024” Report Highlights:

* Nanoparticle Drug Market: US$ 200 Billion Opportunity By 2024
* Global Pipeline For Nanoparticle Drug: 231 Drugs
* Drugs In and Above Phase II Trials: 33 Drugs
* Marketed Nanoparticle Drugs: 13 Drugs
* Dosage, Price and Patent Analysis Of Key Drugs
* Upcoming Nanoparticle Drug Delivery Techniques
* Global Nanoparticle Drug Clinical Pipeline by Company, Indication and Phase

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-nanoparticle-drug-delivery-market,-dosage,-price-and-clinical-pipeline-outlook-2024.php

Table of Contents

1. Nanoparticles - Revolutionizing Drug Delivery Method
1.1 Prologue to Targeted Drug Delivery by Nanoparticles
1.2 Nanoparticle Drug Delivery - Enhancing the Efficacy of Therapeutics by Nanotechnology

2. Need for Nanoparticle Drug Delivery
2.1 Limitations of Traditional Drug Delivery Techniques
2.2 Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology Segment

3. Superiority of Nanoparticle Based Drug Delivery over Traditional Drug Delivery
3.1 Better Therapeutic Outcome than Conventional Drug Delivery Methods
3.2 Role of Nanoparticles in Better Diagnosis of Cancer

4. Importance of Nanoparticle Drug Delivery in Cancer Therapy
4.1 Wide Application of Nanoparticles in Cancer Therapy
4.2 Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging and Therapy

5. Existing Techniques For Nanoparticle Drug Delivery
5.1 Nanocrystals
5.2 Liposomes
5.3 Dendrimers
5.4 Micelle Based Drug Delivery

6. Upcoming Nanoparticle Drug Delivery Techniques
6.1 Polymeric Nanoparticles
6.2 Metal based Nanoparticles (Gold, Iron Oxide)
6.3 Fullerenes and Carbon Nanotube
6.4 Quantum Dots Delivery

7. Global Nanoparticle Drug Market Overview
7.1 Current Market Scenario
7.2 Global Nanoparticle Drug Clinical Pipeline Overview

8. Price and Dosage Analysis of Commercially Available Nanoparticle Therapeutics
8.1 Liposomal Doxorubicin
8.1.1 Availability, Price and Mechanism of Action
8.1.2 Dosage in Various Clinical Indications
8.1.3 Liposomal Doxorubicin (Nanoparticle) v/s Traditional Doxorubicin - Comparative Analysis
8.2 Amphotericin
8.2.1 Availability, Price and Mechanism of Action
8.2.2 Dosage by Indication
8.2.3 Comparative Analysis- Conventional Amphotericin B v/s Nanoparticle Formulations
8.3 Paclitaxel (Taxol, Onxal)
8.3.1 Availability,Price and Mechanism of Action
8.3.2 Dosage Analysis in Various Types of Cancer
8.3.3 Paclitaxel v/s Abraxane(liposomal)
8.4 Sirolimus (Rapamune)
8.4.1 Availability,Price and Mechanism of Action
8.4.2 Rapamune andndash; Dosage Analysis
8.5 Emend (Aprepitant Nanocrystal)
8.5.1 Availability and Price
8.5.2 Dosage Analysis
8.6 Megace ES (Enhanced Stability)
8.6.1 Availability, Price and Mechanism of Action
8.6.2 Comparative Dosage Analyis - Megace v/s Megace ES
8.7 Estradiol Topical Emulsion(Estrasorb)
8.8 Other Nanoparticle Therapeutic Formulations
8.8.1 Feraheme
8.8.2 Triglide - Nanocrystal Version of Tricor

9. Nanoparticle Drug Delivery - Market Trend and Patent Distribution Analysis
9.1 Patent Filing Status in Nanoparticle Drug Delivery
9.2 Patent Distribution by Nanomaterial Type
9.3 Patent Distribution by Stimulus
9.4 Patent Distribution by Route of Administration and Forms of Drug Delivery

10. Driving Factors of Nanoparticle Drug Delivery Market
10.1 Increasing Prevalence of Disease and the Need for Better Therapeutics
10.2 Better Reliability and Safety than Conventional Therapeutics
10.3 Advancement in Research and Development
10.4 Promising Investment and Market Potential
10.5 Rapid Advancement in Innovative and Superior Technology

11. Challenging Aspects of Nanoparticle Drug Delivery Segment
11.1 Highly Expensive Technique and Nanoparticle Products
11.2 Scientific and Technical Limitation Related to Nanoparticles Drug Delivery
11.3 Regional Limitation and Low Market Penetrance
11.4 Dominance of Conventional Drug Delivery Segment

12. Future Forecast and Market Analysis of Global Nanoparticle Drug Delivery Market

13. Global Nanoparticle Drug Clinical Pipeline by Company, Indication and Phase
13.1 Unknown
13.2 Research
13.3 Preclinical
13.4 Clinical
13.5 Phase-I
13.6 Phase-I/II
13.7 Phase-II
13.8 Phase-II/III
13.9 Phase-III
13.10 Preregistration
13.11 Registered

14. Marketed Nanoparticle Drug Clinical Insight by Company and Indication
14.1 Rilpivirine (Edurant)
14.2 Albumin-Bound Paclitaxel (Abraxane, Coraxane and Coroxane)
14.3 Meloxicam (VIVLODEX)
14.4 Ferumoxytol (Feraheme and Rienso)
14.5 Paclitaxel Liposomal - Sun Pharma Advanced Research Company
14.6 Fenofibrate (Lipanthyl and TriCor)
14.7 Doxorubicin Liposomal (Caelyx and Doxil)
14.8 Vincristine Liposomal (Marqibo)
14.9 Fenofibrate (Triglide)
14.10 Rexin-G
14.11 Estradiol Topical (Estrasorb)
14.12 Glycyrrhiza/Phosphatidylcholine (Phosphogliv)
14.13 Paclitaxel Nanoparticle (Nanoxel)

15. Competitive Landscape
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical

Figure 1-1: Evolution of Nanoparticle Drug Delivery
Figure 1-2: Different Drug Delivery Routes
Figure 1-3: Organic Nanoparticles Used in Drug Delivery
Figure 2-1: Limitations of Traditional Drug Delivery Therapy
Figure 2-2: Global- Drug Delivery Segmentation by Route of Administration (%), 2017
Figure 3-1: Superior Characteristic of Nanoparticle Drug Delivery
Figure 3-2: Application of Nanoparticles in Diagnosis
Figure 4-1: Inorganic Nanoparticles Used in Drug Delivery
Figure 4-2: Nanoparticle - Application in Imaging Techniques (%), 2017
Figure 5-1: Nanoparticles Market Segmentation by Types
Figure 5-2: Global- Nanoparticle Drug Delivery Segmentation by Technology (%), 2017
Figure 5-3: Liposome Drug Delivery in Action
Figure 5-4: Dendrimer Nanoparticle in Drug Delivery
Figure 6-1: Gold Nanoparticles in Drug Delivery
Figure 6-2: Fullerenes Being Used as Vectors (Carrying Agents)
Figure 6-3: Quantum Dots in Cancer Therapy
Figure 7-1: Global Nanoparticle Drug Market (US$ Billion), 2013-2017
Figure 7-2: Global - Nanoparticle Drug Clinical Pipeline by Phase (%), 2018 till 2024
Figure 7-3: Global Nanoparticle Clinical Pipeline by Phase (%),2018 till 2024
Figure 8-1: Liposomal Doxorubicin - Availability by Concentration (ml)
Figure 8-2: Adriamycin - Price Analysis (US$/ml), 2018
Figure 8-3: Lipodox 50- Price Analysis (US$), 2018
Figure 8-4: Doxil- Dosage analysis for Ovarian Cancer (mg/m2)
Figure 8-5: Doxil - Dosage Analysis for Kaposi's sarcoma
Figure 8-6: Liposomal Doxorubicin - Dosage Analysis in Multiple Myeloma
Figure 8-7: Doxorubicin (Nanoparticle Variant)- Average Price Analysis (US$/ml), 2018
Figure 8-8: Comparative Dosage Analysis - Traditional Doxorubicin v/s Liposomal Doxorubicin (mg/m2)
Figure 8-9: Doxorubicin- Comparative Price Analysis (US$/mg), 2018
Figure 8-10: Amphotericin B - Availability by Concentration (mg/vial)
Figure 8-11: Conventional Amphotericin B- Dosage Analysis for Adult Fungal Infections (mg/kg)
Figure 8-12: Amphotericin B - Dosage Analysis in Pediatric Fungal Infection (mg/kg)
Figure 8-13: Liposomal Amphotericin B- Dosage Analysis by Indication (mg/kg)
Figure 8-14: Amphotericin B - Comparative Daily Dosage Analysis by Formulation (mg/kg), 2018
Figure 8-15: Amphotericin B-Comparative Price Analysis by Formulation per Day (US$), 2018
Figure 8-16: Comparative Price Analysis - Amphotericin B Nanoparticle Formulations (US$), 2018
Figure 8-17: Paclitaxel - Availability by Concentration (mg and ml)
Figure 8-18: Paclitaxel - Working Mechanism
Figure 8-19: Abraxane- Dosage Analysis by Cancer (mg/Cycle)
Figure 8-20: Paclitaxel Dosage Analysis by Cancer (mg/m2)
Figure 8-21: Price Analysis- Paclitaxel v/s Abraxane (US$), 2018
Figure 8-22: Paclitaxel v/s Abraxane - Comparative Positive Response Rate (%)
Figure 8-23: Rapamune - Availability of Formulations (mg)
Figure 8-24: Rapamune - Cost Analysis by Formulation (US$), 2018
Figure 8-25: Rapamune - Dosage for Low Immune Risk Patients (mg)
Figure 8-26: Rapamune - Dosage for High Immunologic Risk (mg)
Figure 8-27: Emend - Price and Availability (US$), 2018
Figure 8-28: Emend - Dosage Analysis (mg/day)
Figure 8-29: Dosage Analysis - Megace v/s Megace ES (mg/day)
Figure 8-30: Megace v/s Megace ES - Comparative Price Analysis (US$), 2018
Figure 8-31: Estrasorb- Price Analysis (US$), 2018
Figure 8-32: Feraheme - Dosage Analysis (mg/ml)
Figure 8-33: Triglide - Availability by Concentration (mg)
Figure 8-34: Comparative Price Analysis -Triglide and Tricor (US$/Pack), 2018
Figure 9-1: Global- Patent Analysis by Cancer Types (Number), 2016
Figure 9-2: Global - Nanoparticle Patent Filing Status by Region (Numbers), 2016
Figure 9-3: Global- Patent Distribution by Material Type (Numbers), 2016
Figure 9-4: Stimulus of Nanoparticles to Various Factors
Figure 9-5: Global- Patent Distribution by Stimulus (Numbers), 2016
Figure 10-1: Nanoparticle Drug Delivery - Driving Factors
Figure 10-2: Global - Nanoparticle Research in Cancer Segment (By number)
Figure 10-3: Magnetic Nanoparticle - Recent Advances in Drug Delivery
Figure 11-1: Nanoparticle Drug Delivery Market Challenges
Figure 12-1: Global - Nanoparticle Drug Deliver Dominance by Region (%), 2017
Figure 12-2: Global- Nanoparticle Drug Market (US$ Billion), 2018-2024
Figure 12-3: Global- Gold Nanoparticles Future Forecast (US$ Million), 2018 - 2024
Figure 12-4: Global - Investments in the Nanoparticle Drug Delivery Segment (US$ Billion), 2013-2017
Figure 15-1: Arrowhead Research Corporation Clinical Pipeline
Figure 15-2: NanoCarrier Clinical Pipeline






Table 5-1: List Of Commercially Available Nanocrystal Drugs and Their Indication
Table 5-2: Liposome Based Drugs - Current Status
Table 5-3: Current Market Status of Dendrimers
Table 6-4: Traditional Doxorubicin v/s Nanoparticle Doxorubicin

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.